APA (7th ed.) Citation

Moy, R. H., Greally, M., Chou, J. F., Li, J., Desai, A. M., Chalasani, S. B., . . . Ku, G. Y. (2022). Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma. Cancer chemotherapy and pharmacology, 89(2), 255-265. https://doi.org/10.1007/s00280-021-04384-1

Chicago Style (17th ed.) Citation

Moy, Ryan H., et al. "Phase I/Ib Study of Crenolanib with Ramucirumab and Paclitaxel as Second-line Therapy for Advanced Esophagogastric Adenocarcinoma." Cancer Chemotherapy and Pharmacology 89, no. 2 (2022): 255-265. https://doi.org/10.1007/s00280-021-04384-1.

MLA (9th ed.) Citation

Moy, Ryan H., et al. "Phase I/Ib Study of Crenolanib with Ramucirumab and Paclitaxel as Second-line Therapy for Advanced Esophagogastric Adenocarcinoma." Cancer Chemotherapy and Pharmacology, vol. 89, no. 2, 2022, pp. 255-265, https://doi.org/10.1007/s00280-021-04384-1.